PRECIZE INJECTION 3GM

Manufacturer : RAN-RANBAXY LABORATORIES LTD
Composition : CEFOPERAZONE-2000MG+SULBACTAM-1000MG
Dose Form : INJECTION
Description : PRECIZE 3GM INJ
Route Of Administration : PARENTERAL
Pack : 1
Out of stock
SKU
PRE0378
₹546.00
Manufacturer : RAN-RANBAXY LABORATORIES LTD
Composition : CEFOPERAZONE-2000MG+SULBACTAM-1000MG
Dose Form : INJECTION
Description : PRECIZE 3GM INJ
Route Of Administration : PARENTERAL
Pack : 1

Drug Ingredient Information

CEFOPERAZONE-2000MG+SULBACTAM-1000MG

CEFOPERAZONE

Information for patients
Drug Information cefoperazone is indicated for the treatment of the following infections when caused by susceptible organisms: Respiratory Tract Infections caused by S. pneumoniae, H. influenzae, S. aureus (penicillinase and non-penicillinase producing strains), S. pyogenes* (Group A beta-hemolytic streptococci), P. aeruginosa, Klebsiella pneumoniae, E. coli, Proteus mirabilis, and Enterobacter species. Peritonitis and Other Intra-abdominal Infections caused by E. coli, P. aeruginosa,* and anaerobic gram-negative bacilli (including Bacteroides fragilis). Bacterial Septicemia caused by S. pneumoniae, S. agalactiae,* S. aureus, Pseudomonas aeruginosa,* E. coli, Klebsiella spp.,* Klebsiella pneumoniae,* Proteus species* (indole-positive and indole-negative), Clostridium spp.* and anaerobic gram-positive cocci.* Infections of the Skin and Skin Structures caused by S. aureus (penicillinase and non-penicillinase producing strains), S. pyogenes,* and P. aeruginosa. Pelvic Inflammatory Disease, Endometritis, and Other Infections of the Female Genital Tract caused by N. gonorrhoeae, S. epidermidis,* S. agalactiae, E. coli, Clostridium spp.,* Bacteroides species (including Bacteroides fragilis), and anaerobic gram-positive cocci. Cefoperazone , like other cephalosporins, has no activity against Chlamydia trachomatis. Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and C. trachomatis is one of the suspected pathogens, appropriate anti-chlamydial coverage should be added. Urinary Tract Infections caused by Escherichia coli and Pseudomonas aeruginosa. Enterococcal Infections: Although cefoperazone has been shown to be clinically effective in the treatment of infections caused by enterococci in cases of peritonitis and other intra-abdominal infections, infections of the skin and skin structures, pelvic inflammatory disease, endometritis and other infections of the female genital tract, and urinary tract infections,* the majority of clinical isolates of enterococci tested are not susceptible to cefoperazone but fall just at or in the intermediate zone of susceptibility, and are moderately resistant to cefoperazone. However, in vitro susceptibility testing may not correlate directly with in vivo results. Despite this, cefoperazone therapy has resulted in clinical cures of enterococcal infections, chiefly in polymicrobial infections. Cefoperazone should be used in enterococcal infections with care and at doses that achieve satisfactory serum levels of cefoperazone. Susceptibility Testing Before instituting treatment with CEFOBID (sterile cefoperazone) , appropriate specimens should be obtained for isolation of the causative organism and for determination of its susceptibility to the drug. Treatment may be started before results of susceptibility testing are available. Combination Therapy Synergy between CEFOBID (sterile cefoperazone) and aminoglycosides has been demonstrated with many gram-negative bacilli. However, such enhanced activity of these combinations is not predictable. If such therapy is considered, in vitro susceptibility tests should be performed to determine the activity of the drugs in combination, and renal function should be monitored carefully.
Drug Alert
Alert BEFORE THERAPY WITH CEFOBID (sterile cefoperazone) IS INSTITUTED, CAREFUL INQUIRY SHOULD BE MADE TO DETERMINE WHETHER THE PATIENT HAS HAD PREVIOUS HYPERSENSITIVITY REACTIONS TO CEPHALOSPORINS, PENICILLINS OR OTHER DRUGS. THIS PRODUCT SHOULD BE GIVEN CAUTIOUSLY TO PENICILLIN-SENSITIVE PATIENTS. ANTIBIOTICS SHOULD BE ADMINISTERED WITH CAUTION TO ANY PATIENT WHO HAS DEMONSTRATED SOME FORM OF ALLERGY, PARTICULARLY TO DRUGS. SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE THE USE OF SUBCUTANEOUS EPINEPHRINE AND OTHER EMERGENCY MEASURES. PSEUDOMEMBRANOUS COLITIS HAS BEEN REPORTED WITH THE USE OF CEPHALOSPORINS (AND OTHER BROAD-SPECTRUM ANTIBIOTICS); THEREFORE, IT IS IMPORTANT TO CONSIDER ITS DIAGNOSIS IN PATIENTS WHO DEVELOP DIARRHEA IN ASSOCIATION WITH ANTIBIOTIC USE. Treatment with broad-spectrum antibiotics alters normal flora of the colon and may permit overgrowth of clostridia. Studies indicate a toxin produced by Clostridium difficile is one primary cause of antibiotic-associated colitis. Cholestyramine and colestipol resins have been shown to bind the toxin in vitro.Mild cases of colitis may respond to drug discontinuance alone.Moderate to severe cases should be managed with fluid, electrolyte, and protein supplementation as indicated.When the colitis is not relieved by drug discontinuance or when it is severe, oral vancomycin is the treatment of choice for antibiotic-associated pseudomembranous colitis produced by C. difficile. Other causes of colitis should also be considered.
Before Consuming the Medicine
Avoid Drug Although transient elevations of the BUN and serum creatinine have been observed, Ccefoperazone alone does not appear to cause significant nephrotoxicity. However, concomitant administration of aminoglycosides and other cephalosporins has caused nephrotoxicity. It is extensively excreted in bile. The serum half-life of CEFOBID (sterile cefoperazone) is increased 2–4 fold in patients with hepatic disease and/or biliary obstruction. In general, total daily dosage above 4 g should not be necessary in such patients. If higher dosages are used, serum concentrations should be monitored.
Drug Special Care Because renal excretion is not the main route of elimination of , patients with renal failure require no adjustment in dosage when usual doses are administered. When high doses of Cefoperazone are used, concentrations of drug in the serum should be monitored periodically. If evidence of accumulation exists, dosage should be decreased accordingly. The half-life of Cefoperazone is reduced slightly during hemodialysis. Thus, dosing should be scheduled to follow a dialysis period. In patients with both hepatic dysfunction and significant renal disease, Cefoperazone dosage should not exceed 1–2 g daily without close monitoring of serum concentrations. As with other antibiotics, vitamin K deficiency has occurred rarely in patients treated with CEFOBID (sterile cefoperazone) . The mechanism is most probably related to the suppression of gut flora which normally synthesize this vitamin. Those at risk include patients with a poor nutritional status, malabsorption states (e.g., cystic fibrosis), alcoholism, and patients on prolonged hyper-alimentation regimens (administered either intravenously or via a naso-gastric tube). Prothrombin time should be monitored in these patients and exogenous vitamin K administered as indicated. A disulfiram-like reaction characterized by flushing, sweating, headache, and tachycardia has been reported when alcohol (beer, wine) was ingested within 72 hours after Cefoperazone administration. Patients should be cautioned about the ingestion of alcoholic beverages following the administration of Cefoperazone . A similar reaction has been reported with other cephalosporins. Prolonged use of Cefoperazone may result in the overgrowth of nonsusceptible organisms. Careful observation of the patient is essential. If superinfection occurs during therapy, appropriate measures should be taken. Cefoperazone should be prescribed with caution in individuals with a history of gastrointestinal disease, particularly colitis.
Drug Drug Interactions A false-positive reaction for glucose in the urine may occur with Benedict's or Fehling's solution.
Drug Pregnancy Interaction Reproduction studies have been performed in mice, rats and monkeys at doses up to 10 times the human dose and have revealed no evidence of impaired fertility or harm to the fetus due to CEFOBID (sterile cefoperazone) . There are, however, no adequate and well controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.
Drug Breast feeding Interaction Only low concentrations of Cefoperazone are excreted in human milk. Although Cefoperazone passes poorly into breast milk of nursing mothers, caution should be exercised when Cefoperazone is administered to a nursing woman.
Drug Machinery Interaction no data available
Drug More Information no data available
How to take the Medicine
Consumption Info no data available
Drug quanitty The usual adult daily dose of Cefoperazone is 2 to 4 grams per day administered in equally divided doses every 12 hours. In severe infections or infections caused by less sensitive organisms, the total daily dose and/or frequency may be increased. Patients have been successfully treated with a total daily dosage of 6–12 grams divided into 2, 3, or 4 administrations ranging from 1.5 to 4 grams per dose. When treating infections caused by Streptococcus pyogenes, therapy should be continued for at least 10 days.
Drug Dose no data available
Excess Drug Consumption If overdose is suspected, contact your local poison control center or emergency room immediately. US residents can call the US national poison hotline at 1-800-222-1222. Canadian residents should call their local poison control center directly.
Forgot Drug Consumption Consult your pharmacist.
Stop Drug Consumption Do not stop the drug untill your doctor says you to do so.
Possible Side Effects
General Information no data available
Common Drug Side Effects Hypersensitivity: As with all cephalosporins, hypersensitivity manifested by skin reactions, drug fever, or a change in Coombs' test has been reported. These reactions are more likely to occur in patients with a history of allergies, particularly to penicillin. Hematology: As with other beta-lactam antibiotics, reversible neutropenia may occur with prolonged administration. Slight decreases in neutrophil count have been reported. Decreased hemoglobins or hematocrits have been reported, which is consistent with published literature on other cephalosporins. Transient eosinophilia has occurred in 1 patient in 10. Hepatic: Of 1285 patients treated with cefoperazone in clinical trials, one patient with a history of liver disease developed significantly elevated liver function enzymes during cefoperazone therapy. Clinical signs and symptoms of nonspecific hepatitis accompanied these increases. After cefoperazone therapy was discontinued, the patient's enzymes returned to pre-treatment levels and the symptomatology resolved. As with other antibiotics that achieve high bile levels, mild transient elevations of liver function enzymes have been observed in 5–10% of the patients receiving cefoperazone therapy. The relevance of these findings, which were not accompanied by overt signs or symptoms of hepatic dysfunction, has not been established. Gastrointestinal: Diarrhea or loose stools has been reported in 1 in 30 patients. Most of these experiences have been mild or moderate in severity and self-limiting in nature. In all cases, these symptoms responded to symptomatic therapy or ceased when cefoperazone therapy was stopped. Nausea and vomiting have been reported rarely. Symptoms of pseudomembranous colitis can appear during or for several weeks subsequent to antibiotic therapy. Renal Function Tests: Transient elevations of the BUN and serum creatinine have been noted. Local Reactions:Cefoperazone is well tolerated following intramuscular administration. Occasionally, transient pain may follow administration by this route. When Cefoperazone is administered by intravenous infusion some patients may develop phlebitis (1 in 120) at the infusion site.
Rare Drug Side Effects no data available
Very Rare Drug Side Effects no data available
Drug Side Effects Symptoms no data available
How to Store the Medicine
How to Store the Medicine Cefoperazone sterile powder is to be stored at or below 25°C (77°F) and protected from light prior to reconstitution. After reconstitution, protection from light is not necessary. The following parenteral diluents and approximate concentrations of cefoperazone provide stable solutions under the following conditions for the indicated time periods. (After the indicated time periods, unused portions of solutions should be discarded.)

SULBACTAM

Information for patients
Drug Information
Drug Alert
Alert
Before Consuming the Medicine
Avoid Drug
Drug Special Care
Drug Drug Interactions
Drug Pregnancy Interaction
Drug Breast feeding Interaction
Drug Machinery Interaction
Drug More Information
How to take the Medicine
Consumption Info
Drug quanitty
Drug Dose
Excess Drug Consumption
Forgot Drug Consumption
Stop Drug Consumption
Possible Side Effects
General Information
Common Drug Side Effects
Rare Drug Side Effects
Very Rare Drug Side Effects
Drug Side Effects Symptoms
How to Store the Medicine
How to Store the Medicine

Substitute Drugs

Write Your Own Review
You're reviewing:PRECIZE INJECTION 3GM
Your Rating

Get Captcha Image